Oruka Therapeutics, Inc. ORKA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $100.64M-19.2% | $124.62M+12,202% | $1.01M-78.7% | $4.75M-65.7% | ||
| $21.41M+0.5% | $21.31M+239% | $6.28M+7.5% | $5.85M+6.3% | ||
| $122.05M-16.4% | $145.93M+1,900% | $7.3M-31.1% | $10.6M-45.2% | ||
| -$122.05M+16.4% | -$145.93M-1,900% | -$7.3M+31.1% | -$10.6M+45.2% | ||
| $16.62M+290% | $4.26M— | —— | —— | ||
| -$105.43M+25.6% | -$141.67M-2,553% | -$5.34M+46.2% | -$9.93M+48.6% | ||
| -$121.97M+16.4% | -$145.88M-1,904% | -$7.28M+31.2% | -$10.58M+45.3% | ||
| -$122.05M+16.4% | -$145.93M-1,900% | -$7.3M+31.1% | -$10.6M+45.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Oruka Therapeutics, Inc. profitable?
- Oruka Therapeutics, Inc. is not currently profitable: it reported a net loss of $116.3M over the trailing twelve months.
- What is Oruka Therapeutics, Inc.'s earnings per share?
- Oruka Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-6.19.
- Where does Oruka Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.